Denali to Sell Priority Review Voucher for $195M Cash Boost
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval
Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval
Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Capricorn Fund Managers Ltd Acquires New Position in Denali Therapeutics Inc. $DNLI
SG Americas Securities LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of “Moderate Buy” from Analysts
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript
Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
Denali Therapeutics CEO: 2026 Pivotal With Hunter Syndrome FDA Decision and New TV Trial Readouts
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript
Cantor Fitzgerald L. P. Makes New $653,000 Investment in Denali Therapeutics Inc. $DNLI
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference Transcript
FDA reversals leave investors worrying about the fates of other experimental drugs
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
Aberdeen Group plc Buys 210,835 Shares of Denali Therapeutics Inc. $DNLI
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Analysts
Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
Head to Head Comparison: Ultragenyx Pharmaceutical (NASDAQ:RARE) and Denali Therapeutics (NASDAQ:DNLI)
SG Americas Securities LLC Invests $555,000 in Denali Therapeutics Inc. $DNLI
3 Biotech Stocks That Could Double In 2026
Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $284,097.00 in Stock
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
3 Biotech Stocks With Major 2026 Catalysts
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of “Buy” from Analysts
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of “Buy” by Brokerages
Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More